Technology
Health
Biotechnology

Mersana Therapeutics

$2.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.63%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MRSN and other stocks, options, ETFs, and crypto commission-free!

About MRSN

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. Read More The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Employees
86
Headquarters
Cambridge, Massachusetts
Founded
2001
Market Cap
129.80M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
145.85K
High Today
$2.82
Low Today
$2.67
Open Price
$2.78
Volume
244.92K
52 Week High
$15.93
52 Week Low
$2.65

Collections

Technology
Health
Biotechnology
Cancer Prevention
Therapy
2017 IPO
US
North America

MRSN Earnings

-$0.97
-$0.41
$0.14
$0.70
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.38 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.